Protein Sciences takes on Big Pharma in vaccines race

Big Pharma has a big stake in creating new flu vaccines, but tiny Protein Sciences in Connecticut believes it can get a new vaccine approved in '08. The big trend in vaccines today is to move away from egg-based production and into cell-based production, and Protein Sciences' approach is to inject flu genes into caterpillar cells. The protein that is expressed is used in the vaccine. The company may be small, but it has some big names at the top. CEO Daniel Adams is a co-founder of Biogen and David Fedson comes from Sanofi-Aventis.

- read the report from the Wall Street Journal (sub. req.)

Related Article:
Vaccine "renaissance" attracts huge new venture investments. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.